Background And Aim: Quality of life in patients with non-cystic fibrosis (non-CF) bronchiectasis is largely defined by respiratory symptoms. To date, no disease-specific tool for symptom measurement in this patient group was available. We developed the lower respiratory tract infections - visual analogue scale (LRTI-VAS) in order to quickly and conveniently quantify symptoms in non-CF bronchiectasis. This study aimed to validate LRTI-VAS for use in non-CF bronchiectasis.
Methods: This study included outpatients with radiologically proven bronchiectasis and no evidence of CF. Results of LRTI-VAS were compared with other markers of disease activity {lung function parameters, oxygen saturation and three health-related quality of life questionnaires [Medical Outcomes Study Short-Form 36 Health Survey (SF-36), St Georges Respiratory Questionnaire (SGRQ) and Leicester Cough Questionnaire (LCQ)]} and validity, reliability and responsiveness were assessed.
Results: Thirty stable and 30 exacerbating participants completed the LRTI-VAS questionnaire. When testing for repeatability on two separate occasions, no statistically significant difference between total scores was found {1.4 [standard deviation (SD)] 5.3}, P = 0.16). Internal consistency was high across items (Cronbach's alpha 0.86). Correlation with SGRQ, SF-36 and LCQ total scores was high. Following antibiotic treatment, mean (SD) LRTI-VAS total score improved from 18.1 (SD 9.9) to 26.1 (SD 6.6) (P < 0.001).
Conclusions: LRTI-VAS showed excellent validity, reliability and responsiveness to change and therefore appears a reliable tool for symptom measurement in non-CF bronchiectasis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/crj.12198 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lung function trajectories in children with early diagnosis of non-cystic fibrosis bronchiectasis: a retrospective observational study.
Ital J Pediatr
November 2024
Department of Pediatrics, Buzzi Children's Hospital, Milan, Italy.
Background: Non-cystic fibrosis (non-CF) bronchiectasis (BE) is defined as a clinical syndrome of recurrent, persistent wet cough and abnormal bronchial dilatation on chest High Resolution Computed Tomography (HRCT) scans. The aims of this study were to characterize the pattern of the trajectories of lung function parameters and to consider the relationship between the lung function and radiological severity according to the modified Reiff score.
Methods: The study retrospectively considered 86 children (46.
Protein phosphatase 2A activators under investigation for smoking-related chronic obstructive pulmonary disease and related disorders.
Expert Opin Investig Drugs
November 2024
Faculty of Medicine, 3rd Department, University of Medicine and Pharmacy, Carol Davila Bucuresti, Bucuresti, Romania.
Article Synopsis
- Chronic obstructive pulmonary disease (COPD) and other chronic respiratory disorders like cystic fibrosis and alpha-one antitrypsin deficiency share inflammation and progression characteristics, prompting investigations into anti-inflammatory treatments.
- A systematic review of studies from 2000 onward focuses on the role of protein phosphatase 2A (PP2A) in inflammation, its suppression by smoking, and the potential benefits of its activation in treating COPD.
- Experts suggest that activating PP2A could be a viable therapy for COPD and related disorders, highlighting promising avenues like repurposing metformin and inhalation methods, although most evidence is still in the experimental stage.
Article Synopsis
- - Chronic airway inflammation is a major factor in bronchiectasis, influenced by neutrophils that release harmful proteins called neutrophil serine proteases (NSPs) in both cystic fibrosis (CF) and non-CF conditions.
- - There’s an imbalance between NSPs and their counteracting proteins in patients with CF and non-CF bronchiectasis, but effective treatments targeting NSPs are currently lacking.
- - Even with new CFTR modulator therapies improving outcomes for cystic fibrosis patients, airway inflammation remains a problem, highlighting the need for new treatment strategies focused on managing neutrophilic inflammation.
IL-6 and TIMP-1 Correlated to Airway Pathogen Colonization and Predict Disease Severity in Patients with Non-Cystic Fibrosis Bronchiectasis.
J Inflamm Res
August 2024
Department of Pulmonary and Critical Care Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.
Background: Non-cystic fibrosis bronchiectasis is associated with airway pathogen colonization. We planned to investigate the inflammatory markers in patients with different airway pathogens and their correlation with disease severity.
Methods: We enrolled patients aged between 20 and 75 from October 2021 to August 2022.
The Association of Depression with Obstructive Sleep Apnea in Patients with Cystic and Non-Cystic Fibrosis Bronchiectasis.
Life (Basel)
August 2024
Department of Pulmonary Medicine and Intensive Care, Faculty of Medicine, Marmara University, Istanbul 34722, Turkey.
Obstructive sleep apnea (OSA) and cystic fibrosis (CF) are chronic conditions that profoundly impact quality of life. OSA, characterized by repeated episodes of upper airway collapse, can exacerbate CF symptoms due to nocturnal airway obstruction. Recent studies highlight the prevalence of OSA in CF patients, especially in adults, and its detrimental effects on health and quality of life.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!